<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0016-3503</journal-id>
<journal-title><![CDATA[Gen]]></journal-title>
<abbrev-journal-title><![CDATA[Gen]]></abbrev-journal-title>
<issn>0016-3503</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Venezolana de Gastroentereología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0016-35032025000200073</article-id>
<article-id pub-id-type="doi">10.61155/gen.v79i2.736</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación en la vida real de rifaximina para el tratamiento de la diarrea aguda en adultos en Venezuela]]></article-title>
<article-title xml:lang="en"><![CDATA[Real-life evaluation of rifaximin for the treatment of acute diarrhea in adults in Venezuela]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Louis Pérez]]></surname>
<given-names><![CDATA[César Edesio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bernal]]></surname>
<given-names><![CDATA[Melissa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[Ronny]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Catanho]]></surname>
<given-names><![CDATA[Rodolfo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Central de Venezuela  ]]></institution>
<addr-line><![CDATA[Caracas ]]></addr-line>
<country>Venezuela</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad del Rosario  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Caracas  ]]></institution>
<addr-line><![CDATA[Caracas ]]></addr-line>
<country>Venezuerla</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad Central de Venezuela  ]]></institution>
<addr-line><![CDATA[Caracas ]]></addr-line>
<country>Venezuela</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2025</year>
</pub-date>
<volume>79</volume>
<numero>2</numero>
<fpage>73</fpage>
<lpage>80</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://ve.scielo.org/scielo.php?script=sci_arttext&amp;pid=S0016-35032025000200073&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://ve.scielo.org/scielo.php?script=sci_abstract&amp;pid=S0016-35032025000200073&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://ve.scielo.org/scielo.php?script=sci_pdf&amp;pid=S0016-35032025000200073&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  La diarrea constituye un síntoma, no una enfermedad, ya que es una respuesta intestinal inespecífica a diversos estímulos, tales como infecciones, acción directa de toxinas, inflamación o medicamentos.  Objetivo:  Evaluar la eficacia de la rifaximina en la diarrea aguda acuosa profusa de pacientes adultos que acudieron a la consulta externa de medicina general, medicina interna y gastroenterología en el territorio nacional de Venezuela en el periodo marzo- octubre 2022.  Métodos:  Se realizó un estudio naturalístico, abierto, multicéntrico, prospectivo, longitudinal, descriptivo, durante una semana a dosis de rifaximina 400 mg BID por siete días. 84 pacientes cumplieron los criterios de inclusión. Se recolectaron los siguientes datos, tanto en la consulta basal como en las sucesivas recibiendo la rifaximina: nombre, edad, sexo, días con diarrea, frecuencia evacuatoria y tipo de consistencia de heces según la escala de Bristol, así como la presencia de otros síntomas. Se analizaron los datos a partir de técnicas de estadística descriptiva.  Resultados:  La edad promedio fue 51,50 ± 16,10 años, con un rango etario de 19 a 87 años, predominó el género femenino (61,9%). Al comparar la frecuencia de episodios de diarrea antes y durante la administración de rifaximina, se observó que los episodios disminuyeron en el 51%, 76%, y 79%, al 3, 5, 7 día respectivamente. La eficacia y la seguridad evaluada por médicos y pacientes fueron excelentes en la mayoría de los casos. No hubo efectos adversos en el 96%.  Conclusión:  El uso empírico de la rifaximina en diarreas agudas acuosas profusas, es efectivo y seguro.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Diarrhea is a symptom, not a disease, since it is a nonspecific intestinal response to various stimulus, such as infections, direct action of toxins, inflammation or medications.  Objective:  To evaluate the effectiveness of rifaximin in acute profuse watery diarrhea in adult patients who attended the outpatient clinic of general medicine, internal medicine and gastroenterology in the national territory of Venezuela in the period March-October 2022.  Methods:  A study was naturalistic, open, multicenter, prospective, longitudinal, descriptive, for one week at a dose of rifaximin 400 mg BID for seven days. 84 patients met the inclusion criteria. The following data were collected, both in the baseline consultation and in subsequent visits receiving rifaximin: name, age, sex, days with diarrhea, evacuation frequency and type of stool consistency according to the Bristol scale, as well as the presence of other symptoms. The data were analyzed using descriptive statistics techniques.  Results:  The average age was 51.50 ± 16.10 years, with an age range of 19 to 87 years, the female gender predominated (61.9%). When comparing the frequency of diarrhea episodes before and during the administration of rifaximin, it was observed that the episodes decreased by 51%, 76%, and 79%, at 3, 5, and 7 days, respectively. Efficacy and safety evaluated by doctors and patients were excellent in most cases. There were no adverse effects in 96%.  Conclusion:  The empirical use of rifaximin in acute profuse watery diarrhea is effective and safe.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[diarrea infecciosa aguda]]></kwd>
<kwd lng="es"><![CDATA[diarrea del viajero]]></kwd>
<kwd lng="es"><![CDATA[rifaximina]]></kwd>
<kwd lng="es"><![CDATA[diarrea acuosa]]></kwd>
<kwd lng="en"><![CDATA[acute infectious diarrhea]]></kwd>
<kwd lng="en"><![CDATA[traveler's diarrhea]]></kwd>
<kwd lng="en"><![CDATA[rifaximin]]></kwd>
<kwd lng="en"><![CDATA[watery diarrhea]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Heaton]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stool form scale as a useful guide to intestinal transit time]]></article-title>
<source><![CDATA[Scand J Gastroenterol]]></source>
<year>1997</year>
<volume>32</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>920-4</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schiller]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Sellin]]></surname>
<given-names><![CDATA[JH. Diarrhea]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sleisenger and Fordtran&#8217;s]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Lawrence]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Brandt]]></surname>
<given-names><![CDATA[LJ.]]></given-names>
</name>
</person-group>
<source><![CDATA[Gastrointestinal and Liver Disease]]></source>
<year>2021</year>
<edition>11th</edition>
<page-range>204-23</page-range><publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DuPont]]></surname>
<given-names><![CDATA[H L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute infectious diarrhea in immunocompetent adults]]></article-title>
<source><![CDATA[N Eng J Med]]></source>
<year>2014</year>
<volume>370</volume>
<page-range>1532-40</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kyoung]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Joo]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rifaximin for the treatment of acute infectious diarrhea]]></article-title>
<source><![CDATA[Ther Adv Gastroenterol]]></source>
<year>2011</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>227235</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pawlowski]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Warren C]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Guerrant]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and treatment of acute or persistent diarrhea]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2009</year>
<volume>136</volume>
<page-range>1874-86</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diaz Mora]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Echezuria]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Petit]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Cardozo]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Arias]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Risquez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diarrea aguda: Epidemiología, concepto, clasificación, clínica, diagnóstico, vacuna contra rotavirus]]></article-title>
<source><![CDATA[Arch Venez Puer Ped]]></source>
<year>2014</year>
<volume>77</volume>
<page-range>29-40</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Connor]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Riddle]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postinfectious sequelae of travelers&#8217; diarrhea]]></article-title>
<source><![CDATA[J Travel Med]]></source>
<year>2013</year>
<volume>20</volume>
<page-range>303-12</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zaidi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wine]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An update on travelers&#8217; diarrhea]]></article-title>
<source><![CDATA[Curr Opin Gastroenterol]]></source>
<year>2015</year>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-13</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koo]]></surname>
<given-names><![CDATA[H.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Dupont]]></surname>
<given-names><![CDATA[H.L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases]]></article-title>
<source><![CDATA[Curr Opin Gastroenterol]]></source>
<year>2010</year>
<volume>26</volume>
<page-range>1725</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camilleri]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[J.A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diarrhea and constipation]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Fauci]]></surname>
<given-names><![CDATA[A.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Kasper]]></surname>
<given-names><![CDATA[D.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Hauser]]></surname>
<given-names><![CDATA[S.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Longo]]></surname>
<given-names><![CDATA[D.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Jameson]]></surname>
<given-names><![CDATA[J.L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Harrison&#8217;s Principles of Internal Medicine]]></source>
<year>2008</year>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[McGraw-Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gobernado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ponce]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rifaximina]]></article-title>
<source><![CDATA[Rev Esp Quimioterap]]></source>
<year>2004</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>141-53</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guerrant]]></surname>
<given-names><![CDATA[R.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Van Gilder]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Steiner]]></surname>
<given-names><![CDATA[T.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Thielman]]></surname>
<given-names><![CDATA[N.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Slutsker]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Tauxe]]></surname>
<given-names><![CDATA[R.V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practice guidelines for the management of infectious diarrhea]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2001</year>
<volume>32</volume>
<page-range>331351</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DuPont]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rifaximin: An Antibiotic with Important Biologic Effects]]></article-title>
<source><![CDATA[Mini Rev Med Chem]]></source>
<year>2015</year>
<volume>16</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>200-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ponziani]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of antibiotics in gut microbiota modulation: the eubiotic effects of rifaximin]]></article-title>
<source><![CDATA[Dig Dis]]></source>
<year>2016</year>
<volume>34</volume>
<page-range>269-78</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ponziani]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
<name>
<surname><![CDATA[Zocco]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[D'Aversa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pompili]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gasbarrini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation]]></article-title>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2017</year>
<volume>23</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>4491-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ivashkin]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Shifrin]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Maslennikov]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Poluektova]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Korolev]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kudryavtseva]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Krasnov]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Benuni]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Barbara]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eubiotic effect of rifaximin is associated with decreasing abdominal pain in symptomatic uncomplicated diverticular disease: results from an observational cohort study]]></article-title>
<source><![CDATA[BMC Gastroenterol]]></source>
<year>2023</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>82</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Novoa-Farias]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Frati-Munari]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Peredo]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Flores Juarez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Novoa-Garcia]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Galicia-Tapia]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Romero-Carpio]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Susceptibilidad de las bacterias aisladas de infecciones gastrointestinales agudas a la rifaximina y otros agentes antimicrobianos en México]]></article-title>
<source><![CDATA[Rev Gastroenterol Méx]]></source>
<year>2016</year>
<volume>81</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-10</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real-World Evidence: A Primer]]></article-title>
<source><![CDATA[Pharmaceut Med]]></source>
<year>2023</year>
<volume>37</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-36</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dumitrascu]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Bakulin]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Berzigotti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cravo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gombo&#353;ová]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lukas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pietrzak]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Remes-Troche]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Romero-Gómez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Balmori]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Gonçalves]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Hamzaoui]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Juricek]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Neubauer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Surdea-Blaga]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tikhonov]]></surname>
<given-names><![CDATA[IN]]></given-names>
</name>
<name>
<surname><![CDATA[Trna]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ianiro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ponziani]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
<name>
<surname><![CDATA[Gasbarrini]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Update on the Role of Rifaximin in Digestive Diseases]]></article-title>
<source><![CDATA[J Gastrointestin Liver Dis]]></source>
<year>2023</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>92-109</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bielsa-Fernandez]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Frati-Munari]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Ariza-Andraca]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento a pacientes con diarrea aguda: encuesta a un grupo de médicos generales de México]]></article-title>
<source><![CDATA[Aten Fam]]></source>
<year>2016</year>
<volume>23</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>119-24</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acuña]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diarrea Aguda]]></article-title>
<source><![CDATA[Rev Med Clin Condes]]></source>
<year>2015</year>
<volume>26</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>676-86</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[ZD]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[DuPont]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pretreatment of epitelial cells with rifaximin alters bacterial attachment and internalization profiles]]></article-title>
<source><![CDATA[Antimicrob Agent Chemother]]></source>
<year>2010</year>
<volume>54</volume>
<page-range>388-96</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fiorucci]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Distrutti]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mencarelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Morelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodenmt model of colitis]]></article-title>
<source><![CDATA[Digestion]]></source>
<year>2002</year>
<volume>66</volume>
<page-range>246-56</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DuPont]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic effects and mechanisms of action of rifaximin in gastrointestinal diseases]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>2015</year>
<volume>90</volume>
<page-range>1116-24</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berman]]></surname>
<given-names><![CDATA[A.L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea]]></article-title>
<source><![CDATA[J Clin Gastroenterol]]></source>
<year>2007</year>
<volume>41</volume>
<page-range>932-3</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garey]]></surname>
<given-names><![CDATA[K.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[Z.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Bellard]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Dupont]]></surname>
<given-names><![CDATA[H.L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study]]></article-title>
<source><![CDATA[J Clin Gastroenterol]]></source>
<year>2009</year>
<volume>43</volume>
<page-range>91-3</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Jang]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of rifaximin compared with ciprofloxacin for the treatment of acute infectious diarrhea: a randomized controlled multicenter study]]></article-title>
<source><![CDATA[Gut Liver]]></source>
<year>2010</year>
<volume>4</volume>
<page-range>357-62</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luttichau]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[Arcangeli]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Sinapi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of rifaximin in the treatment of acute diarrhoeal enteritis: open study]]></article-title>
<source><![CDATA[Panminerva Med]]></source>
<year>1985</year>
<volume>27</volume>
<page-range>129-32</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Schriever]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Hecht]]></surname>
<given-names><![CDATA[D.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Gerding]]></surname>
<given-names><![CDATA[D.N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment]]></article-title>
<source><![CDATA[Anaerobe]]></source>
<year>2009</year>
<volume>15</volume>
<page-range>290-1</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[D.N.]]></given-names>
</name>
<name>
<surname><![CDATA[Bourgeois]]></surname>
<given-names><![CDATA[A.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Ericsson]]></surname>
<given-names><![CDATA[C.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Steffen]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[Z.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Halpern]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers&#8217; diarrhea]]></article-title>
<source><![CDATA[Am J Trop Med Hyg]]></source>
<year>2006</year>
<volume>74</volume>
<page-range>1060-6</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steffen]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Sack]]></surname>
<given-names><![CDATA[D.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Riopel]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[Z.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Sturchler]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ericsson]]></surname>
<given-names><![CDATA[C.D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapy of travelers&#8217; diarrhea with rifaximin on various continents]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2003</year>
<volume>98</volume>
<page-range>1073-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
